- Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653. doi:10.1086/432579
- Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859-1867. doi:10. 1111/j. 1469-0691.2010.03456.x
- Sridhara SR, Paragache G, Panda NK, Chakrabarti A. Mucormycosis in immunocompetent individuals: an increasing trend. J Otolaryngol. 2005;34(6):402-406. doi:10.2310/7070.2005.34607
- Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402. doi:10. 1093/ mmy/ myy060
- Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43. doi:10.1093/mmy/myx017
- Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates (published correction appears in PLoS One. 2020 Feb 12;15(2):e0229347). PLoS One. 2017; 12(6): e0179136. Published 2017 Jun 7. doi: 10. 1371/ journal.pone.0179136
- Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-837. doi:10.1016/S1473-3099(16)00071-2
- Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010; 48(3):511-517. doi: 10.3109/ 13693780903 311944
- Legrand M, Gits-Muselli M, Boutin L, et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment. Clin Infect Dis. 2016;63(10):1312-1317. doi:10.1093/cid/ciw563
- Revannavar SM, P S S, Samaga L, V K V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?. BMJ Case Rep. 2021; 14(4): e241663. Published 2021 Apr 27. doi:10.1136/bcr-2021-241663
- Gamaletsou MN, Sipsas NV, Roilides E, Walsh TJ. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14(4):423-434. doi: 10. 1007/ s11908-012-0272-6
- Abbasi AZ, Kiyani DA, Hamid SM, Saalim M, Fahim A, Jalal N. Spiking dependence of SARS-CoV-2 pathogenicity on TMPRSS2. J Med Virol. 2021;93(7):4205-4218. doi:10.1002/jmv.26911
- Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. Published 2020 Mar 17. doi:10.1128/JVI.00127-20
- Iwata-Yoshikawa N, Okamura T, Shimizu Y, Hasegawa H, Takeda M, Nagata N. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. J Virol. 2019;93(6):e01815-18. Published 2019 Mar 5. doi:10.1128/JVI.01815-18
- Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020;12(9):e10726. Published 2020 Sep 30. doi:10.7759/cureus.10726
- Yao Y, Wang H, Liu Z. Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases. Clin Exp Allergy. 2020; 50(12): 1313-1324. doi:10.1111/cea.13746
- Armstrong-James D, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 2014;22(3):120-127. doi:10.1016/j.tim.2014.01.001
- Cassone A, Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS. 2012;26(12):1457-1472. doi: 10. 1097/QAD.0b013e3283536ba8
- Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017;31(2):17-29. doi: 10.1016/j.blre.2016.09.002
- Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018; 6(10):782-792. doi:10.1016/S2213-2600 (18) 30274-1.
- Jaiswal AS, Sikka K, Bhalla AS, et al. Facial neuritis in coronavirus disease 2019 associated mucormycosis: study on clinico-radiological correlates. J Laryngol Otol. 2022;136(4):349-353. doi:10.1017/S0022215121003510
- Singh A, Goel G, Khan M, Kanodia A, Sikka K, Thakar A. Factors affecting clinical outcome in COVID-associated rhino-orbito-cerebral mucormycosis (CAROM) patients-An ambispective, single-arm, observational study (published online ahead of print, 2023 Jul 16). Am J Otolaryngol. 2023;44(6):103975. doi: 10. 1016/j. amjoto. 2023.103975
- Morton CO, Griffiths JS, Loeffler J, Orr S, White PL. Defective antifungal immunity in patients with COVID-19. Front Immunol. 2022;13:1080822. Published 2022 Nov 30. doi: 10.3389/ fimmu. 1080822
- Lee IT, Nakayama T, Wu CT, et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun. 2020; 11(1): 5453. Published 2020 Oct 28. doi: 10. 1038/ s41467-020-19145-6.
|